Name | Raphin1 acetate |
Description | Raphin1 acetate is a selective and orally bioavailable regulatory phosphatase PPP1R15B (R15B) inhibitor. |
In vitro | Raphin1, a selective inhibitor of R15B.?In cells, Raphin1 caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis.?In vitro, Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment. |
In vivo | Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 40 mg/mL (137.4 mM), Sonication is recommended.
|
Keywords | Raphin1 | Phosphatase | Raphin-1 acetate | Raphin-1 | Raphin1 acetate | Raphin 1 | Raphin1 Acetate | inhibit | Inhibitor |
Inhibitors Related | PTP1B-IN-22 | Disodium monofluorophosphate | β-Glycerophosphate disodium salt pentahydrate | MLS000544460 | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | Trimyristin | β-Glycerophosphate disodium salt hydrate |
Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Phosphatase Inhibitor Library |